Literature DB >> 17583355

Pharmacology of N-desmethylclozapine.

Jelveh Lameh1, Ethan S Burstein, Eve Taylor, David M Weiner, Kimberly E Vanover, Douglas W Bonhaus.   

Abstract

Currently available treatments for schizophrenia have limited efficacy and are generally poorly tolerated. However, among these antipsychotic agents, clozapine stands apart in having generally superior motoric tolerability and efficacy. One intriguing possibility, based on clinical correlations, receptor activity profiles and studies with animal models predictive of antipsychotic or cognitive action is that the activity of N-desmethylclozapine (NDMC), a major metabolite of clozapine, may, at least in part, underlie the unique efficacy of clozapine. In this review we compare the pharmacological properties of NDMC to those of clozapine and consider how they may contribute to the overall clinical properties of clozapine. We also consider whether NDMC, in its own right, might be a superior antipsychotic drug.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17583355     DOI: 10.1016/j.pharmthera.2007.05.004

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  22 in total

1.  Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo.

Authors:  Marie Humbert-Claude; Elisabeth Davenas; Florence Gbahou; Ludwig Vincent; Jean-Michel Arrang
Journal:  Psychopharmacology (Berl)       Date:  2011-09-13       Impact factor: 4.530

Review 2.  The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review.

Authors:  Christoffer Polcwiartek; Jimmi Nielsen
Journal:  Psychopharmacology (Berl)       Date:  2015-12-02       Impact factor: 4.530

3.  Pharmacological characterization of M1 muscarinic acetylcholine receptor-mediated Gq activation in rat cerebral cortical and hippocampal membranes.

Authors:  Yuji Odagaki; Masakazu Kinoshita; Ryoichi Toyoshima
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-09       Impact factor: 3.000

4.  Metabolism and Distribution of Clozapine-N-oxide: Implications for Nonhuman Primate Chemogenetics.

Authors:  Jessica Raper; Ryan D Morrison; J Scott Daniels; Leonard Howell; Jocelyne Bachevalier; Thomas Wichmann; Adriana Galvan
Journal:  ACS Chem Neurosci       Date:  2017-03-30       Impact factor: 4.418

5.  Different pharmacology of N-desmethylclozapine at human and rat M2 and M 4 mAChRs in neocortex.

Authors:  S Gigout; S Wierschke; C Dehnicke; R A Deisz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-01-16       Impact factor: 3.000

6.  Further characterization of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in C57BL/6 mice: role of 5-HT(2A) serotonergic and alpha (1) adrenergic antagonism.

Authors:  Scott D Philibin; D Matthew Walentiny; Sarah A Vunck; Adam J Prus; Herbert Y Meltzer; Joseph H Porter
Journal:  Psychopharmacology (Berl)       Date:  2008-11-07       Impact factor: 4.530

Review 7.  Better pharmacotherapy for schizophrenia: what does the future hold?

Authors:  Michael A Webber; Stephen R Marder
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

8.  The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic drug clozapine in rats.

Authors:  Adam J Prus; Alan L Pehrson; Scott D Philibin; Jesse T Wood; Sarah A Vunck; Joseph H Porter
Journal:  Psychopharmacology (Berl)       Date:  2008-08-07       Impact factor: 4.530

Review 9.  A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia.

Authors:  Martin Sarter; Vicente Martinez; Rouba Kozak
Journal:  Psychopharmacology (Berl)       Date:  2008-07-10       Impact factor: 4.530

10.  Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms.

Authors:  Kathryn K Erickson-Ridout; Dongxiao Sun; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2012-08       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.